Budget impact of introducing oral semaglutide to the public healthcare benefit package in Saudi Arabia

References

• Health Sector Transformation Program; Delivery Plan. 2021. Ministry of Health, Kingdom of Saudi Arabia. https://www.vision2030.gov.sa/media/p2lfgxe4/delivery-plan-en-hstp.pdf. Accessed 18 June 2023.
   Google Scholar
• Vision 2030—Kingdom of Saudi Arabia. Council of Economic and Development Affairs, Government of Saudi Arabia. https://www.vision2030.gov.sa/media/rc0b5oy1/saudi_vision203.pdf. Accessed 18 June 2023.
   Google Scholar
• International Diabetes Federation. IDF diabetes atlas. International Diabetes Federation, Brussels, Belgium, 8th edition, 2017. http://www.diabetesatlas.org. Accessed 16 June 2023.
   Google Scholar
• Al Dawish MA, Robert AA, Braham R, et al. Diabetes mellitus in Saudi Arabia: a review of the recent literature. Curr Diabetes Rev. 2016;12(4):359–368. doi: 10.2174/1573399811666150724095130.
   PubMedGoogle Scholar
• Al-Jedai AH, Almudaiheem HY, Alissa DA, et al. Cost of cardiovascular diseases and renal complications in people with type 2 diabetes mellitus in the kingdom of Saudi Arabia: a retrospective analysis of claims database. PLoS One. 2022;17(10):e0273836. doi: 10.1371/journal.pone.0273836.
   PubMed Web of Science ®Google Scholar
• Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD). Diabetes Care. 2022;45(11):2753–2786. doi: 10.2337/dci22-0034.
   PubMed Web of Science ®Google Scholar
• Saudi Diabetes Clinical Practice Guidelines (SDCPG), Saudi National Diabetes Center (SNDC), Saudi Health Council. 2021. https://shc.gov.sa/Arabic/Documents/SDCP%20Guidelines.pdf. Accessed 18 June 2023.
   Google Scholar
• Fonseca VA. Defining and characterizing the progression of type 2 diabetes. Diabetes Care. 2009; 32(Suppl 2):S151–S6. doi: 10.2337/dc09-S301.
   PubMedGoogle Scholar
• Alromaih A, Alshamrani A, Alharbi B, et al. Saudi consensus for oral semaglutide, the recent innovation in GLP-1 RAs era; consensus report. JDM. 2023;13(02):222–238. doi: 10.4236/jdm.2023.132017.
   Google Scholar
• Alhagawy AJ, Yafei S, Hummadi A, et al. Barriers and attitudes of primary healthcare physicians to insulin initiation and intensification in Saudi Arabia. IJERPH. 2022;19(24):16794. doi: 10.3390/ijerph192416794.
   Web of Science ®Google Scholar
• Bain SC, Bekker Hansen B, Hunt B, et al. Evaluating the burden of poor glycemic control associated with therapeutic inertia in patients with type 2 diabetes in the UK. J Med Econ. 2020;23(1):98–105. doi: 10.1080/13696998.2019.1645018.
   PubMed Web of Science ®Google Scholar
• Khayyat SM, Mohamed MMA, Khayyat SMS, et al. Association between medication adherence and quality of life of patients with diabetes and hypertension attending primary care clinics; a cross-sectional survey. Qual Life Res. 2019;28(4):1053–1061. doi: 10.1007/s11136-018-2060-8.
   PubMed Web of Science ®Google Scholar
• Josh SR, Rajput R, Chowdhury S, et al. The role of oral semaglutide in managing type 2 diabetes in Indian clinical settings: addressing the unmet needs. Diabetes Metab Syndr. 2022;16(6):102508. doi: 10.1016/j.dsx.2022.1025081871-4021.
   PubMed Web of Science ®Google Scholar
• World Health Organization. 2016. Available at: http://www.who.int/mediacentre/factsheets/fs311/en/. Accessed 16 June 2023.
   Google Scholar
• Wondmkun YT. Obesity, insulin resistance, and type 2 diabetes: associations and therapeutic implications. Diabetes Metab Syndr Obes. 2020; 13:3611–3616. doi: 10.2147/DMSO.S275898.
   PubMed Web of Science ®Google Scholar
• Hansen BB, Nuhoho S, Ali SN, et al. Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis. J Med Econ. 2020;23(6):650–658. doi: 10.1080/13696998.2020.1722678.
   PubMed Web of Science ®Google Scholar
• Fasseeh A, Karam R, Jameleddine M, et al. Implementation of health technology assessment in the Middle east and North africa: comparison between the current and preferred status. Front Pharmacol. 2020;11:15. doi: 10.3389/fphar.2020.00015.
   PubMed Web of Science ®Google Scholar
• Maraiki F, Bazarbashi S, Scuffham P, et al. Methodological approaches to cost-effectiveness analysis in Saudi Arabia: what can we learn? A systematic review. MDM Policy Pract. 2022;7(1):23814683221086869. doi: 10.1177/23814683221086869.
   Google Scholar
• Diabetes Atlas. 2021, IDF diabetes Atlas, Saudi Arabia, https://diabetesatlas.org/data/en/country/174/sa.html. Accessed 15 Aug 2022.
   Google Scholar
• Brown JB, Conner C, Nichols GA. ‘Secondary failure of metformin monotherapy in clinical practice’. Available at: https://www.researchgate.net/publication/40812417_Secondary_Failure_of_Metformin_Monotherapy_in_Clinical_Practice.
   Google Scholar
• Tucker M. 2023, ‘Metformin Monotherapy Not Always Best Start in Type 2 Diabetes’. Available at: https://www.medscape.com/viewarticle/986994?&icd=login_success_email_match_fpf.
   Google Scholar
• Saudi Census. 2022. General Authority for Statistics of the Kingdom of Saudi Arabia; https://portal.saudicensus.sa/portal/public/1/18/101511?type=TABLE.
   Google Scholar
• GASTAT Database. General Authority for Statistics of the Kingdom of Saudi Arabia; https://database.stats.gov.sa/home/indicator/535.
   Google Scholar
• Open Data Library. Council of Health Insurance; Kingdom of Saudi Arabia. https://chi.gov.sa/OpenData/Pages/Documents/2021.pdf.
   Google Scholar
• World Health Survey Saudi Arabia. 2019. Ministry of Health, Kingdom of Saudi Arabia. https://www.moh.gov.sa/en/Ministry/Statistics/Population-Health-Indicators/Documents/World-Health-Survey-Saudi-Arabia.pdf.
   Google Scholar
• Malkin JD, Baid D, Alsukait RF, et al. The economic burden of overweight and obesity in Saudi Arabia. Plos One. 2022;17(3):e0264993. doi: 10.1371/journal.pone.0264993.
   PubMed Web of Science ®Google Scholar
• Rodbard HW, Rosenstock J, Canani LH, et al. Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial. Diabetes Care. 2019;42(12):2272–2281. doi: 10.2337/dc19-0883.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Allison D, Birkenfeld AL, et al. Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial. JAMA. 2019;321(15):1466–1480. doi: 10.1001/jama.2019.2942.
   PubMed Web of Science ®Google Scholar
• Alqahtani SA, Al-Omar HA, Alshehri A, et al. Obesity burden and impact of weight loss in Saudi Arabia: a modelling study. Adv Ther. 2023;40(3):1114–1128. doi: 10.1007/s12325-022-02415-8.
   PubMed Web of Science ®Google Scholar
• Medicine Market Intelligence Reports. IQVIA Institute for Human Data Science. 2022. Accessed 15 Aug 2022.
   Google Scholar
• Raghavan S, Vassy JL, Ho Y-L, et al. Diabetes mellitus-related all-cause and cardiovascular mortality in a national cohort of adults. J Am Heart Assoc. 2019;8(4):e011295. doi: 10.1161/JAHA.118.011295.
   PubMed Web of Science ®Google Scholar
• Kothari V, Stevens RJ, Adler AI, et al. UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK prospective diabetes study risk engine. Stroke. 2002;33(7):1776–1781. doi: 10.1161/01.str.0000020091.07144.c7.
   PubMed Web of Science ®Google Scholar
• Mulnier HE, Seaman HE, Raleigh VS, et al. Risk of myocardial infarction in men and women with type 2 diabetes in the UK: a cohort study using the general practice research database. Diabetologia. 2008;51(9):1639–1645. doi: 10.1007/s00125-008-1076-y.
   PubMed Web of Science ®Google Scholar
• Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841–851. doi: 10.1056/NEJMoa1901118.
   PubMed Web of Science ®Google Scholar
• Leiter LA, Bain SC, Hramiak I, et al. Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial. Cardiovasc Diabetol. 2019;18(1):73. doi: 10.1186/s12933-019-0871-8.
   PubMedGoogle Scholar
• Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121–130. doi: 10.1016/S0140-6736(19)31149-3.
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322. doi: 10.1056/NEJMoa1603827.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128. doi: 10.1056/NEJMoa1504720.
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–357. doi: 10.1056/NEJMoa1812389.
   PubMed Web of Science ®Google Scholar
• Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232–242. doi: 10.1056/NEJMoa1501352.
   PubMed Web of Science ®Google Scholar
• Chen D-Y, Li Y-R, Mao C-T, et al. Cardiovascular outcomes of vildagliptin in patients with type 2 diabetes mellitus after acute coronary syndrome or acute ischemic stroke. J Diabetes Investig. 2020;11(1):110–124. doi: 10.1111/jdi.13078.
   PubMed Web of Science ®Google Scholar
• Li Y-R, Tsai S-S, Chen D-Y, et al. Linagliptin and cardiovascular outcome in type 2 diabetes after acute coronary syndrome or acute ischemic stroke. Cardiovasc Diabetol. 2018;17(1):2. doi: 10.1186/s12933-017-0655-y.
   PubMedGoogle Scholar
• Bailey C, Gross J, Pieters A, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glyaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375:223–2233.
   Web of Science ®Google Scholar
• Bosi E, Camisasca RP, Collober C, et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care. 2007;30(4):890–895. doi: 10.2337/dc06-1732.
   PubMed Web of Science ®Google Scholar
• Taskinen M-R, Rosenstock J, Tamminen I, et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2011;13(1):65–74. doi: 10.1111/j.1463-1326.2010.01326.x.
   PubMed Web of Science ®Google Scholar
• Pratley RE, Aroda VR, Lingvay I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018;6(4):275–286. doi: 10.1016/S2213-8587(18)30024-X.
   PubMed Web of Science ®Google Scholar
• Alzaid A, Ladrón de Guevara P, Beillat M, et al. Burden of disease and costs associated with type 2 diabetes in emerging and established markets: systematic review analyses. Expert Rev Pharmacoecon Outcomes Res. 2021;21(4):785–798. doi: 10.1080/14737167.2020.1782748.
   PubMed Web of Science ®Google Scholar
• Khalid SA, Samia AB, Bandari KA. Hypertension in Saudi adults with type 2 diabetes. Interventions Obes Diab. 2018; 1(4). doi: 10.31031/IOD.2018.01.000518.
   Google Scholar
• Alzaheb R, Altemani A. Prevalence and associated factors of dyslipidemia among adults with type 2 diabetes mellitus in Saudi Arabia. DMSO. 2020;13:4033–4040. https://dovepress.com/getfile.php?fileID=62983 doi: 10.2147/DMSO.S246068.
   Google Scholar
• Almutairi N, Alkharfy KM. Direct medical cost and glycemic control in type 2 diabetic saudi patients. Appl Health Econ Health Policy. 2013;11(6):671–675. doi: 10.1007/s40258-013-0065-6.
   PubMedGoogle Scholar
• Almalki Z, Alatawi Y, Alharbi A, et al. Cost-effectiveness of more intensive blood pressure treatment in patients with high risk of cardiovascular disease in Saudi Arabia. Int J Hypertens. 2019;2019:6019401. doi: 10.1155/2019/6019401.
   PubMed Web of Science ®Google Scholar
• Hnoosh A, Vega-Hernández G, Jugrin A, et al. PDB45 direct medical costs of diabetes-related complications in Saudi Arabia. Value in Health. 2012;15(4):A178. doi: 10.1016/j.jval.2012.03.966.
   Web of Science ®Google Scholar
• Expert Opinion.
   Google Scholar
• Osman AM, Alsultan MS, Al-Mutairi MA. The burden of ischemic heart disease at a major cardiac center in Central Saudi Arabia. Saudi Med J. 2011; 32(12):1279–1284.
   PubMed Web of Science ®Google Scholar